國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Personalized therapy for multiple my...

Nooka, Ajay K.

Personalized therapy for multiple myeloma

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Personalized therapy for multiple myelomaedited by Saad Z. Usmani, Ajay K. Nooka.
其他作者:	Usmani, Saad Z.
出版者:	Cham :Springer International Publishing :2018.
面頁冊數:	ix, 178 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Multiple myelomaTreatment.
電子資源:	http://dx.doi.org/10.1007/978-3-319-61872-2
ISBN:	9783319618722$q(electronic bk.)

Personalized therapy for multiple myeloma
Personalized therapy for multiple myeloma[electronic resource] /edited by Saad Z. Usmani, Ajay K. Nooka. - Cham :Springer International Publishing :2018. - ix, 178 p. :ill., digital ;24 cm.

Risk stratification in newly diagnosed smoldering multiple myeloma -- Risk stratification in newly diagnosed transplant eligible multiple myeloma -- Risk stratification in newly diagnosed transplant ineligible multiple myeloma -- Treatment of translocation 4;14 and deletion 17 p MM -- Treatment of patients in first/second relapse -- Treatment of patients in third relapse and beyond including double refractory disease -- Treatment of primary and secondary plasma cell leukemia -- Practical considerations for bone health in multiple myeloma -- Personalizing MM treatment: gaps in knowledge that we need to overcome.

This book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews and evidence-based recommendations for treatment are presented. The coverage encompasses all phases and forms of disease, including high-risk myeloma. Over recent decades, greater understanding of the biology of myeloma has fostered the development of new, more effective drugs, leading to remarkable improvements in survival. To continue this momentum, several recent prospective trials have aimed to identify further potential therapeutic targets or to evaluate various combinations of anti-myeloma agents. The increasing abundance of management options makes treatment decision making in different phases of disease. This book will offer the clinician valuable assistance in the choice and sequencing of therapies, highlighting the need for a personalized approach that reflects the growing recognition that myeloma is not one uniform disease.

ISBN: 9783319618722$q(electronic bk.)

Standard No.: 10.1007/978-3-319-61872-2doiSubjects--Topical Terms:

470647
Multiple myeloma
--Treatment.

LC Class. No.: RC280.B6

Dewey Class. No.: 616.99418

Personalized therapy for multiple myeloma
LDR:02649nmm a2200313 a 4500 001 528874
003 DE-He213
005 20180621171326.0
006 m d
007 cr nn 008maaau
008 181030s2018 gw s 0 eng d
020 $a 9783319618722$q(electronic bk.)
020 $a 9783319618715$q(paper)
024 7 $a 10.1007/978-3-319-61872-2 $2 doi
035 $a 978-3-319-61872-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.B6
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99418 $2 23
090 $a RC280.B6 $b P467 2018
245 0 0 $a Personalized therapy for multiple myeloma $h [electronic resource] / $c edited by Saad Z. Usmani, Ajay K. Nooka.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a ix, 178 p. : $b ill., digital ; $c 24 cm.
505 0 $a Risk stratification in newly diagnosed smoldering multiple myeloma -- Risk stratification in newly diagnosed transplant eligible multiple myeloma -- Risk stratification in newly diagnosed transplant ineligible multiple myeloma -- Treatment of translocation 4;14 and deletion 17 p MM -- Treatment of patients in first/second relapse -- Treatment of patients in third relapse and beyond including double refractory disease -- Treatment of primary and secondary plasma cell leukemia -- Practical considerations for bone health in multiple myeloma -- Personalizing MM treatment: gaps in knowledge that we need to overcome.
520 $a This book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews and evidence-based recommendations for treatment are presented. The coverage encompasses all phases and forms of disease, including high-risk myeloma. Over recent decades, greater understanding of the biology of myeloma has fostered the development of new, more effective drugs, leading to remarkable improvements in survival. To continue this momentum, several recent prospective trials have aimed to identify further potential therapeutic targets or to evaluate various combinations of anti-myeloma agents. The increasing abundance of management options makes treatment decision making in different phases of disease. This book will offer the clinician valuable assistance in the choice and sequencing of therapies, highlighting the need for a personalized approach that reflects the growing recognition that myeloma is not one uniform disease.
650 0 $a Multiple myeloma $x Treatment. $3 470647
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Oncology. $3 195181
650 2 4 $a Hematology. $3 274899
700 1 $a Usmani, Saad Z. $3 801543
700 1 $a Nooka, Ajay K. $3 801544
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-61872-2
950 $a Medicine (Springer-11650)